A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED, FIXED-DOSE, EFFICACY, AND SAFETY STUDY OF SHP465 IN CHILDREN AGED 6-12 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)

UT Health San Antonio

The UT Health San Antonio, with missions of teaching, research and healing, is one of the country’s leading health sciences universities.

Principal Investigator(s)

Pliszka, Steven R

Funded by

SHIRE PHARMACEUTICAL DEVELOPMENT INC

Research Start Date

05/01/2018

Status

Active

Collaborative Project

Clinical Care

Drug Discovery

Other

Bioscience Research Panel